Mariko Harada-Shiba, Michael H Davdison, Marc Ditmarsch, Andrew Hsieh, Erin Wuerdeman, Douglas Kling, Annie Nield, Mary R Dicklin, Akitaka Nakata, Atsushi Sueyoshi, Satoshi Kuroyanagi, John J P Kastelein
AIMS: Obicetrapib is a highly selective cholesteryl ester transfer protein (CETP) inhibitor shown to reduce low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB), when taken as monotherapy and in combination with ezetimibe on a background of statins, in clinical trials predominantly conducted in Northern European/Caucasian participants. We characterized the efficacy, safety, and tolerability of obicetrapib within an Asian-Pacific region population. METHODS: This double-blind, randomized, phase 2 trial examined obicetrapib 2...
April 3, 2024: Journal of Atherosclerosis and Thrombosis